Hyaluronidase
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Hyaluronidase: Predicted New Indication — Esotropia (Evidence Under Review)
One-Sentence Summary
Hyaluronidase (DB14740) has no confirmed original indication or marketing authorisation on record in the data reviewed. The TxGNN model’s top-ranked prediction is Esotropia, but this is currently supported by only 1 publication and no registered clinical trials — and that single publication describes a surgical complication (post-cataract-surgery diplopia/strabismus), not a treatment effect. This candidate should be treated as an unverified signal, not a therapeutic hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no UK marketing authorisation or original indication on record |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for hyaluronidase in this evidence pack, and no original indication or UK licence could be identified to anchor a mechanistic comparison.
The sole supporting publication (PMID 16934027) describes persistent diplopia and strabismus as a complication of retrobulbar local anaesthesia during cataract surgery — hyaluronidase is a common additive in such anaesthetic mixtures. This is a case-report description of an adverse ocular motility outcome associated with the drug’s use, not evidence of a therapeutic effect on esotropia.
As a result, the TxGNN score for this candidate more plausibly reflects a co-occurrence between hyaluronidase exposure and strabismus/diplopia as an adverse event rather than a genuine repurposing opportunity. The mechanistic direction is, if anything, a risk signal rather than a treatment rationale, and should not be interpreted as supportive evidence without further scrutiny.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16934027 | 2006 | Case report | Binocular Vision & Strabismus Quarterly | Reports persistent diplopia and strabismus as a complication following cataract surgery under local (retrobulbar) anaesthesia containing hyaluronidase; describes clinical features and management of the complication, not a treatment effect. |
UK Market Information
No UK marketing authorisation is currently on record for hyaluronidase in the dataset reviewed (0 licences, market status: not marketed).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (esotropia) is supported by a single case report describing an adverse surgical complication rather than a therapeutic effect, with no clinical trials and no mechanism-of-action data available to build a repurposing rationale. Evidence is insufficient to proceed.
To proceed, the following is needed:
- Confirmed original indication(s) and mechanism of action for hyaluronidase (currently both are data gaps)
- UK marketing authorisation / SmPC data, since none is currently on record
- Clinical or mechanistic evidence that directly supports a therapeutic (not adverse-event) association between hyaluronidase and esotropia
- TFDA/MHRA-equivalent warning and contraindication data to allow a baseline safety assessment (currently blocking per data gap DG001)
Note on other candidates in this evidence pack: among the 10 TxGNN-ranked predictions for this drug, diabetic retinopathy (rank 6) has materially stronger evidence — two completed Phase 3 trials (NCT00198510, n=750; NCT00198497, n=510) of intravitreal hyaluronidase (Vitrase) for vitreous haemorrhage clearance, plus a supporting Phase 2 study and 20 literature references — and may warrant separate evaluation. However, the underlying rationale notes this indication was historically not granted regulatory approval on efficacy grounds, so the two Phase 3 trials’ primary endpoint outcomes would need to be verified before this is pursued as a distinct candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.